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Monitored anesthesia care (MAC) is useful for various clinical 
fields such as minimally invasive surgery, gastrointestinal 
endoscopy, and interventional or radiological procedures. It 
provides suitable intraoperative conditions as well as comfort for 
patients. The commonly used drugs are midazolam, propofol, 
and opioids such as fentanyl, alfentanil or remifentanil. 
Occasionally, the administration of sedatives or hypnotics in 
conjunction with analgesics can cause significant respiratory 
depression and/or transient upper airway obstruction. 
Dexmedetomidine is a highly selevtive α2-adrenoceptor 
agonist with eight times higher specificity for the receptor 
compared to clonidine. It provides excellent sedation and 
analgesia with minimal respiratory depression [1]. Recent 
multicenter trial indicated that it was an effective baseline 
sedative for patients undergoing a broad range of surgical 
procedures under MAC, providing greater patient satisfaction, 
less opioid requirements, and less respiratory depression 
compared with the placebo [2]. In patients undergoing 
diagnostic transesophageal echocardiography, the sedative 
effect of dexmedetomidine proved to be equivalent to that 
of the standard therapy using midazolam and fentanyl 
without increasing the incidences of respiratory depression 
or oxygen desaturation. It also seemed to be better in terms 
of hemodynamic results [3]. Dexmedetomidine with fentanyl 
could be used safely and effectively for sedation and analgesia 
during extracorporeal shockwave lithotripsy [4].
In the current issue of the Korean Journal of Anesthesiology 
[5], the authors demonstrated dexmedetomidine was a useful 
sedative drug for MAC in outpatients undergoing cataract 
surgery, and in aspects of patients’ satisfaction and cardiovas-
cular stability, it was superior to the combination of propofol 
and alfentanil. 
However, Muller et al. [6] have showed dexmedetomidine 
alone was not as effective as propofol with fentanyl for 
providing conscious sedation during ERCP. Furthermore, it was 
associated with greater hemodynamic instability and longer 
recovery time. Spontaneously breathing pediatrics patients 
undergoing cardiac catheterization with dexmedetomidine and 
ketamine experienced insufficient sedation and analgesia and 
prolonged recovery compared to propofol and ketamine [7]. 
Dexmedetomidine leads to dose-dependent decreases in 
blood pressure, heart rate, and plasma catecholamine concent-
rations [8,9]. Higher concentrations of this drug can also 
result in systemic and pulmonary hypertension [10]. Severe 
bradycardia progressing to pulseless electrical activity caused 
by dexmedetomidine was reported in a 74-year-old man who 
experienced a postoperative myocardial infarction [11]. These 
adverse effects on cardiovascular system might limit the use of 
high concentrations of dexmedetomidine, and clinicians must 
always be careful when using this drug, especially in patients 
with significant cardiac disease. 
Rapid administration of dexmedetomidine can lead to 
transi  ent hypertension, bradycardia, or tachycardia, and there-
fore, administration of a loading dose for over 10 minutes is 
recommended [12]. The drug is sometimes used without a 
loading dose [11]. The report, published in the current issue of 
the Korean Journal of Anesthesiology [5], suggested continuous 
infusion of dexmedetomidine adjusted depending on the 
sedation scale without a loading dose neither disturbing 
cardiovascular stability nor delaying discharge.
It is necessary to monitor blood pressure even after discon-
tinuation of dexmedetomidine as its infusion for 2 minutes has 
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induced a long-lasting decrease in mean arterial blood pressure 
in the healthy volunteers, with a maximum decrease of 14% 
for 0.25 μg/kg and 16% for 0.5 μg/kg at 60 minutes after the 
discontinuance of the drug [13]. 
Although dexmedetomidine is an attractive drug for MAC, 
further studies on appropriate dosage according to patients’ 
age or race or the presence of other drugs and on the method 
of infusion suitable for each procedures are required for safe 
use. The use of dexmedetomidine in pediatric patients is not yet 
approved in Korea.
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